Paclitaxel (Taxol)

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Paclitaxel is a novel antineoplastic agent, which was discovered in a screen of extracts of thousands of plants and natural products for antineoplastic activity by a National Cancer Institute program. Alought it functions as a mitotic inhibitor like vinca alkaloids, paclitaxel promotes the polymerization of tubulin instead of inducing the disassembly of microtubules, which inhibits the microtubules disassembly and promotes the formation of excessively stable, dysfunctional microtubules. Paclitaxel has exhibited antitumor activity against a broad spectrum of human cancers, including ovarian, breast, head and neck, and lung cancer, in a large number of studies.
    
    Reference:
    Ross C. Donehower. The clinical development of paclitaxel: a successful collaboration of academia, industry and the National cancer Institute. STEM CELLS 1996;14:25-28
- Properties
  - Categories
    
    Antineoplastic agent
    
    Alternative Name
    
    Taxol
    
    CAS Number
    
    33069-62-4
    
    Molecular Formula
    
    C47H51NO14
    
    Molecular Weight
    
    853.91
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥42.7 mg/mL in DMSO; insoluble in H2O; insoluble in H2O; ≥29.53 mg/mL in EtOH with ultrasonic; ≥31.6 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    SMILES
    
    O=C(N[[email protected]]([[email protected]](C(O[[email protected]]1C[[email protected]]2(O)C(C)(C)C([[email protected]@H](OC(C)=O)C([[email protected]@]3(C)[[email protected]]([[email protected]@](CO4)(OC(C)=O)[[email protected]]4C[[email protected]@H]3O)([H])[[email protected]@H]2OC(C5=CC=CC=C5)=O)=O)=C1C)=O)O)C6=CC=CC=C6)C7=CC=CC=C7
    
    * For Research Use Only
- Reference
  - 1. Shengli Dong, Hassan Yousefi, et al. "Ceritinib is a novel triple negative breast cancer therapeutic agent." Mol Cancer. 2022 Jun 29;21(1):138. PMID: 35768871
    2. Prateek Bhardwaj, Vikram Gota, et al. "Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy." J Control Release. 2022 Mar;343:288-302. PMID: 35101477
    3. Mikhail S. Chesnokov, Marianna Halasi, et al. "Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells." Cell Death Dis. 2021 Jul 14;12(7):704. PMID: 34262016
    4. Anirban Roychowdhury, Mayur Jondhale, et al. "Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8." Gene. 2021 Aug 5;792:145728. PMID: 34022297
    5. Catherine Suzanne Snyder. "Polymer Nanoparticle Design for Ovarian Cancer Therapies." University of Michigan 2021.
    6. Juanwen Lian, Tao Hua, et al. "Interleukin-1β weakens paclitaxel sensitivity through regulating autophagy in the non-small cell lung cancer cell line A549." Exp Ther Med. 2021 Apr;21(4):293. PMID: 33717236
    7. Chu xue, Si-Xue Liu, et al. "Corydalis Saxicola Bunting Total Alkaloids Inhibits Paclitaxel-Induced Peripheral Neuropathy By Regulating PKCε-TRPV1 and p38 MAPK-TRPV1 Signaling Pathways." Research Square. doi.org/10.21203/rs.3.rs-332970/v1.
    8. Yongman Liu, Jianye Wang, et al. "Quantifying 3D cell–matrix interactions during mitosis and the effect of anticancer drugs on the interactions." Nano Research. ISSN 1998-0124 CN 11-5974/O4.
    9. Shahbandi A, Rao SG, et al. "BH3 mimetics selectively eliminate chemotherapy-induced senescent cells and improve response in TP53 wild-type breast cancer." Cell Death Differ. 2020;10.1038/s41418-020-0564-6. PMID: 32457483
    10. Gamache JE, Kemper L, et al. "Developmental pathogenicity of 4-repeat human tau is lost with the P301L mutation in genetically matched tau-transgenic mice." J Neurosci. 2019 Nov 4. pii: 1256-19. PMID: 31685653
    11. Tonnessen-Murray CA, Frey WD, et al. "Chemotherapy-induced senescent cancer cells engulf other cells to enhance their survival." J Cell Biol. 2019 Sep 17. pii: jcb.201904051. PMID: 31530580
    12. Chung HK, Zou X, et al. "A compact synthetic pathway rewires cancer signaling to therapeutic effector release." Science. 2019 May 3;364(6439). PMID: 31048459
    13. Zhang Y, Xia F, et al. "miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2." J Exp Clin Cancer Res. 2019 Jan 21;38(1):26. PMID: 30665445
    14. Deng Y, Li F, et al. "Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition." Mol Carcinog. 2018 Jun;57(6):807-814. PMID: 29500880
    15. Zina Hamoudi , Thang Manh Khuong, et al. "A fruit fly model for studying paclitaxel-induced pain [version 1;referees: awaiting peer review]" F1000Research 23 Jan 2018, 7:99.
    16. Yu Wang, Zhenxin Zhu, et al. "The effect of phenotypic conditioned medium on the proliferation of BGC823 in human gastric cancer cell line." Academic Journal of Second Military Medical University, Dec.2017, Vol.38, No.12.